Second Primaries in Nearly Quarter of Metastatic Prostate Cancer Cases

Share this content:
More than one-quarter of patients with metastatic prostate cancer present with a synchronous second primary malignancy.
More than one-quarter of patients with metastatic prostate cancer present with a synchronous second primary malignancy.

More than one-quarter of patients with metastatic prostate cancer present with a synchronous second primary malignancy, according to a review published in The Journal of Urology.

Kyo Chul Koo, M.D., Ph.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues conducted a retrospective record review of 582 consecutive patents with prostate cancer diagnosed with metastasis. 

The authors examined the prognostic impact of a synchronous second primary malignancy, defined as a cytologically or histologically proven solid malignancy, on overall survival.

The researchers found that 28.1 percent of patients had a synchronous second primary malignancy, of which the most prevalent types were colorectal (9.1 percent), stomach (7.3 percent), and lung (7.1 percent) cancers.

During a median follow-up of 34.1 months, the rate of overall survival was significantly higher for patients without a synchronous secondary primary malignancy versus those with lung or stomach cancer.

RELATED: Under, Over Imaging Suspected for Prostate Cancer Care

Outcomes were comparable for men without a second malignancy and for those with colorectal cancer. Independent predictors of overall mortality included clinical stage T4 or greater, American Society of Anesthesiologists score 1 or greater, and lung or stomach cancer.

"A substantial proportion of patients with metastatic prostate cancer present with a synchronous second primary malignancy," the authors write.

"Definitive therapy targeting prostate cancer may confer a limited survival benefit in patients with synchronous lung or stomach cancer."

Reference

  1. Koo, Kyo Chul, et al. "Prognostic Impact of Synchronous Second Primary Malignancies on the Overall Survival of Patients with Metastatic Prostate Cancer." The Journal of Urology. DOI: http://dx.doi.org/10.1016/j.juro.2014.10.088. [epub ahead of print]. October 23, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs